TARA Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Protara Therapeutics's net margin of 8.48%. Protara Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Protara Therapeutics has a consensus price target of $28.00, signalling upside risk potential of 373.77%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25%. Given that Protara Therapeutics has higher upside potential than Eli Lilly and, analysts believe Protara Therapeutics is more attractive than Eli Lilly and.

Protara Therapeutics has a beta of 1.562, which suggesting that the stock is 56.229% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Protara Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protara Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Protara Therapeutics's net income of -$11.2M is lower than Eli Lilly and's net income of $970.3M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 85.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus 17.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Protara Therapeutics's net margin of -49.65%. Protara Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Protara Therapeutics has a consensus price target of $28.00, signalling upside risk potential of 373.77%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 483.4%. Given that NovaBay Pharmaceuticals has higher upside potential than Protara Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Protara Therapeutics.

Protara Therapeutics has a beta of 1.562, which suggesting that the stock is 56.229% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Protara Therapeutics's net income of -$11.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Protara Therapeutics's net margin of 25.23%. Protara Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

Protara Therapeutics has a consensus price target of $28.00, signalling upside risk potential of 373.77%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that Protara Therapeutics has higher upside potential than Pfizer, analysts believe Protara Therapeutics is more attractive than Pfizer.

Protara Therapeutics has a beta of 1.562, which suggesting that the stock is 56.229% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. Protara Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Protara Therapeutics's net income of -$11.2M is lower than Pfizer's net income of $4.5B. Notably, Protara Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Protara Therapeutics's net margin of -2357.27%. Protara Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Protara Therapeutics has a consensus price target of $28.00, signalling upside risk potential of 373.77%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1316.67%. Given that Palatin Technologies has higher upside potential than Protara Therapeutics, analysts believe Palatin Technologies is more attractive than Protara Therapeutics.

Protara Therapeutics has a beta of 1.562, which suggesting that the stock is 56.229% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Protara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protara Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Protara Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Protara Therapeutics's net income of -$11.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Protara Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protara Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.